D-0861-2022 Class II Terminated

Recalled by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) — Rockford, IL

FDA drug recall D-0861-2022 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Apr 1, 2022 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: OOS result was obtained for Any Other Individual Impurity at the 12M room temperature time point. The recall status is terminated (terminated Jun 9, 2023). Affected quantity: 885 cartons.

Recall details

Product Type
Drugs
Report Date
May 18, 2022
Initiation Date
Apr 1, 2022
Termination Date
Jun 9, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
885 cartons

Product description

Esomeprazole Magnesium Delayed-Release Capsules, USP 40 mg, packaged in Unit Dose Blister Cards of 6 (10 cards of 6 Capsules each per carton), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC 42292-010-16

Reason for recall

Failed Impurities/Degradation Specifications: OOS result was obtained for Any Other Individual Impurity at the 12M room temperature time point.

Distribution pattern

Nationwide within USA

Code information

Lot #: 3110437, 3111409, 3110785, Exp. Date 7/31/2022; 3112173, Exp. Date 11/30/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0861-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0861-2022. Report a data issue: hello@regdatalab.com.